Glioblastoma Tumours: Complex Challenges and Deadly Outcomes
DOI:
https://doi.org/10.15173/m.v1i27.1164Abstract
Glioblastoma (GBM) tumours are the most common primary brain tumours among adults, with many treatment challenges. In addition to being highly malignant and fatal tumours, GBMs are also heterogeneous in tissue and genetic composition, difficult to target, frequently recurring and often treatment-resistant. As a result of these challenges, GBM treatment has been essentially unchanged for decades, with minute improvements in patient prognosis, despite active research efforts. Currently, patients have a mean survival time of less than fifteen months. This article aims to explore the current questions in GBM research, including the role and limitations of surgery and chemotherapy treatments, the relationship between age and prognosis, and the controversy surrounding the optimal extent of resection. Additionally, this article outlines the impact of notable research developments in the field, including the role of nanotechnology in the first successful chemo-radiotherapy treatment on otherwise treatment-resistant GBM cells.
References
Holland EC. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci. 2000 Jun 6;97(12):6242–4.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med. 2005;352(10):987– 96.
Ghose A, Lim G, Husain S. Treatment for glioblas- toma multiforme: current guidelines and Cana- dian practice. Curr Oncol. 2010 Nov;17(6):52–8.
Harsh GR 4th, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neu- rosurgery. 1987 Nov;21(5):615–21.
Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of te- mozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000 Sep;83(5):588–93.
Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al. Disease progres- sion or pseudoprogression after concomitant ra- diochemotherapy treatment: Pitfalls in neuroon- cology. Neuro-Oncol. 2008 Jun 1;10(3):361–7.
Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, Mc- Dermott MW, et al. Impact of extent of resection for recurrent glioblastoma on overall survival. Neurosurg. 2012 Oct 5;117(6):1032–8.
Krex D, Klink B, Hartmann C, Deimling A von, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain. 2007 Oct 14. 1;67(9):4010–5.
Sun S, Lee D, Leung GKK. Chemoresistance in 1;130(10):2596–606. Glioma. In: Lee NP, Cheng CY, Luk JM, editors.
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98–110. 15.
Cooper LAD, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al. The Proneural Molecu-lar Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas. PLoS ONE. 2010 Sep 3;5(9):e12548.
Lima FRS, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca ACC, et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochem Biophys Acta. 2012 Dec;1826(2):338–49.
Mrugala MM. Advances and Challenges in the Treatment of Glioblastoma: A Clinician’s Perspective. Discov Med. 2013 Apr 25;15(83):221–30.
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular Profiles. Cancer Res. 2007 May1;67(9):4010–5.
Sun S, Lee D, Leung GKK. Chemoresistance in Glioma. In: Lee NP, Cheng CY, Luk JM, editors. New Advances on Disease Biomarkers and Molecular Targets in Biomedicine [Internet]. Human Press; 2013 [cited 2014 Jul 25]. p. 243–70. Available from: http://link.springer.com/chapter/10.1007/978-1-62703-456-2_14
Haar CP, Hebbar P, Iv GCW, Das A, Iii WAV, Smith JA, et al. Drug Resistance in Glioblastoma: A Mini Review. Neurochem Res. 2012 Jun 1;37(6):1192–2000
Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al. Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme. J Clin Oncol. 2010 Aug 20;28(24):3838–43.
Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998 Apr;42(4):709–720; discussion 720–723.
Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, et al. Analysis of Complex Relationships between Age, p53, Epidermal Growth Factor Receptor, and Survival in Glioblastoma Patients. Cancer Res. 2001 Feb 2;61(3):1122–8.
Batchelor TT, Betensky RA, Esposito JM, Pham L-DD, Dorfman MV, Pisca- telli N, et al. Age-Dependent Prognostic Effects of Genetic Alterations in Glio- blastoma. Clin Cancer Res. 2004 Jan 1;10(1):228–33.
LeeY,ScheckAC,CloughesyTF,LaiA, Dong J, Farooqi HK, et al. Gene expres- sion analysis of glioblastomas identifies the major molecular basis for the prog- nostic benefit of younger age. BMC Med Genomics. 2008 Oct 21;1(1):52.
Phillips HS, Kharbanda S, Chen R, For- rest WF, Soriano RH, Wu TD, et al. Mo- lecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006 Jan 3;9(3):157–73.
Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly. Cancer. 2009 Aug 15;115(16):3758–66.
Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH. Outcome in elderly patients undergoing definitive surgery and radiation therapy for su- pratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol. 1998 Dec 1;42(5):981–7.
Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, et al. Supratentorial Glioblastoma Multi- forme: The Role of Surgical Resection Versus Biopsy Among Older Patients. Ann Surg Oncol. 2011 Jan 1;18(1):239– 45.
Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, et al. Surgical outcomes for older pa- tients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg. 2011 Mar;114(3):587–94.
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of pa- tients with glioblastoma: Recursive par- titioning analysis. Neuro-Oncol. 2004 Jul 1;6(3):227–35.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: progno- sis, extent of resection, and survival. J Neurosurg. 2001 Aug;95(2):190–8.
Barbagallo GMV, Jenkinson MD, Brod- belt AR. “Recurrent” glioblastoma mul- tiforme, when should we reoperate? Br J Neurosurg. 2008 Jan 1;22(3):452–5.
GondaDD,WarnkeP,SanaiN,TaichZ, Kasper EM, Chen CC. The value of ex- tended glioblastoma resection: Insights from randomized controlled trials. Surg Neurol Int [Internet]. 2013 Aug 28 [cited 2014 Jun 6];4. Available from: http:// www.ncbi.nlm.nih.gov/pmc/articles/ PMC3768170/
Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, et al. An extent of resection threshold for recur- rent glioblastoma and its risk for neu- rological morbidity. J Neurosurg. 2014 Apr;120(4):846–53.
DeVita VT. The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Im- plications for surgical adjuvant treat- ment of cancer. Cancer. 1983 Apr 1;51(7):1209–20.
Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolo- mide: a review of its discovery, chemi- cal properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997 Jan;23(1):35–61.
Hegi ME, Diserens A-C, Gorlia T, Ham- ou M-F, de Tribolet N, Weller M, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med. 2005;352(10):997–1003.
Rostomily R, Spence A, Duong D, Mc- Cormick K, Bland M, Berger M. Multimo- dality Management of Recurrent Adult Malignant Glioma: Results of a Phase II Multiagent Chemotherapy Study and Analysis of Cytoreductive Surgery. Neurosurgery. 1994 Sep;35(3):378–88.
Mandl ES, Dirven CMF, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage thera- py. Surg Neurol. 2008 May;69(5):506– 9.
Setua S, Ouberai M, Piccirillo SG, Watts C, Welland M. Cisplatin-tethered gold nanospheres for multimodal chemo-ra- diotherapy of glioblastoma. Nanoscale. 2014 Aug 21;6(18):10865–73.
